Skip to content




About PLN-74809

PLN-74809 directly acts on the development of liver and bile duct fibrosis (scarring) by blocking the activity of a protein in your body called TGF-beta. This is different than UDCA or other medications that mainly improve bile flow and inflammation.

Thinking of taking part?

  1. Check how suitable you are by looking at the information below.
  2. Check our map to see if you can get to a study site.
  3. Contact the research team for more details if you think you are suitable. Check back regularly as we are adding more contact info every day.
  4. Got a question? Our Clinical Trials Pack has lots of information about how to join clinical trials, switching hospitals for trials and what's involved.
  5. Contact us if you need any help.

Key information (updated 10 May 2024)


Trial Name PLN-74809-PSC-203 Identifier NCT04480840
Phase Phase 2a trial
Intervention Oral tablet once a day
Recruiting now? FULLY RECRUITED
Participating Centres See current sites list on or contact
Liver disease diagnosis Confirmed large duct PSC
Age 18 to 75 years old
Females: can I be pregnant? No
Is IBD allowed? Patients with IBD are allowed but must be on a stable treatment regimen for 12 weeks before Screening. Biologics, immunosuppressives and other therapies are all allowed.
Is there an ALP (alkaline phosphatase) requirement? Serum (measured in a blood test) ALP should be within normal ranges or greater 1 time the upper limit of the normal range (ULN) at Screening.
Can I take UDCA (Urso)? Yes. Both UDCA treated and untreated patients are allowed but must be at a stable dose for 12 weeks before Screening
Can I take part if I have a stent? No stents allowed
Are recent acute cholangitis (ie bacterial cholangitis) attacks allowed? Patients must be free of acute cholangitis infections for 60 days before Screening and no episodes during the Screening period
Can I take part if I have had a liver transplant? Patients who have had a liver transplant cannot take part. You may be on the waiting list for the transplant but cannot have one scheduled.
Is cirrhosis allowed? No
Previous studies and information See Pliant website
Are travel expenses covered? Patients will be reimbursed for reasonable travel and overnight if needed
Procedures and tests include: Physical exams, blood and urine laboratory tests and patient surveys at most visits. FibroScan is required at Screening and end of treatment. MRI is optional. No liver biopsy is required for this study.
How many study visits will there be? How long will each study visit be? A total of 8 visits which generally last 1-3 hours. Home health services are offered as part of the study and most visits can be conducted remotely if desired.
Duration of study Up to 42-day Screening, Minimum 24-week - up to 48-week treatment and 4-week post-treatment follow-up (up to 58 weeks)
Basic design of study Randomised, placebo controlled with a 3:1 randomisation (75% chance of getting study drug)
Link to Sponsor Pliant Therapeutics

Take control

Understand your care and what to expect

What is PSC?

What exactly is PSC? We've got the basics covered #PSCFacts

PSC and Me

Read about the experiences of others living with PSC